The European Commission Approved Regeneron Product Dupixent® as Maintenance Treatment for Adults with Uncontrolled COPD

Impacting News July 5, 2024

Regeneron in the NEWS
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY . . .

This content is for paid subscribers.

Please click here to subscribe or here to log in.

Impacting News
Regeneron Pharmaceuticals (REGN), Sanofi (SNY)
July 5, 2024

Tweet Pin It

Other Articles

Regenxbio Announces Positive Results of its Product RGX-121 for Hunter Syndrome

September 5, 2024 0

Good News for Vertex Pharmaceuticals and for Crispr Therapeutics

August 27, 2024 0

Cytokinetics Reports Management Update and Q2 2024 Financial Results

August 12, 2024 0

Exelixis Announces Q2 2024 Financial Results and Provides Corporate Update

August 7, 2024 0

Search ProhostBiotech

Popular Links
Aerie Pharmaceuticals (AERI) Agenus (AGEN) Alnylam Pharmaceuticals (ALNY) Amgen (AMGN) Array BioPharma (ARRY) AstraZeneca Plc (AZN) Bellicum Pharmaceuticals Inc (BLCM) Bristol-Myers Squibb (BMY) Celgene (CELG) Celldex Therapeutics (CLDX) Cellectis (CLLS) Celyad (CYAD) Compugen (CGEN) CRISPR Therapeutics (CRSP) CytomX Therapeutics Inc (CTMX) Editas Medicine Inc (EDIT) Enanta Pharmaceuticals (ENTA) Exelixis (EXEL) Gilead Sciences (GILD) Halozyme Therapeutics (HALO) Illumina (ILMN) ImmunoGen (IMGN) Incyte (INCY) Innoviva (INVA) Intellia Therapeutics (NTLA) Ionis Pharmaceuticals Inc (IONS) Karyopharm Therapeutics Inc (KPTI) Merck (MRK) Moderna Inc (MRNA) Nektar Therapeutics (NKTR) Neurocrine Biosciences (NBIX) Novartis (NVS) Portola Pharmaceuticals Inc (PTLA) PTC Therapeutics (PTCT) Regeneron Pharmaceuticals (REGN) Regenxbio (RGNX) Rhythm Pharmaceuticals Inc (RYTM) Sangamo Therapeutics Inc (SGMO) Sarepta Therapeutics (SRPT) Seagen Inc (SGEN) Spark Therapeutics Theravance Biopharma (TBPH) Vertex Pharmaceuticals (VRTX) Xoma (XOMA)

Recent

ProhostBiotech Archive
ProhostBiotech Archive
Sign Up for Weekly Emails
First Name

Last Name

Email address:

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Accept Privacy policy

Exclusive Market Insight

& Scientific analysis

The European Commission Approved Regeneron Product Dupixent® as Maintenance Treatment for Adults with Uncontrolled COPD